On April 27,2025, at the achievement release event for the Shenzhen Qianhai-Shekou Area of the Guangdong Free Trade Zone, Shenzhen-Hong Kong Cell Valley (Shenzhen) Medical Technology Co., Ltd. was awarded the "Top Ten Key Investment Projects of the Shenzhen Qianhai-Shekou Area in China (Guangdong) Pilot Free Trade Zone" honor plaque. Professor Shi Yuanyuan, founder of the company, attended the event as a representative of key enterprises and shared the strategic development plan for Shenzhen-Hong Kong Cell Valley in the Qianhai area.

Shi Yuanyuan stated in an interview that the pilot policy jointly issued by three national ministries holds groundbreaking significance, as it is the first time foreign-funded enterprises are permitted to conduct research and application of human stem cell and gene diagnosis/therapy technologies within the free trade zone, opening up a new track for businesses. As one of the first enterprises in Guangdong Free Trade Zone to benefit from the national medical openness pilot policies, Shenzhen-Hong Kong Cell Valley will leverage Qianhai as its strategic pivot, focusing on the international frontier of cell and gene therapy. The company actively builds a collaborative innovation mechanism between Shenzhen and Hong Kong to promote a new development model integrating medical services with industrialization. Building on Cell Valley Group's core technological expertise in cell therapy—particularly its unique industrial-scale production technology for retroviral vectors—the group has established a full-industry-chain platform covering R&D, manufacturing, and medical services. He emphasized that Qianhai's geographical advantage of being "a bridge away" from Hong Kong provides natural convenience for efficient international capital connections and global client acquisition. Additionally, the Qianhai Administration's full-process support services—from registration and site selection to talent coordination and tax clearance—have enabled the company to complete establishment within three months, with operations expected to commence in May 2025. Positioned as the international business and medical service headquarters of Cell Valley Group, Shenzhen-Hong Kong Cell Valley delivers high-end cell and gene therapy solutions to the Guangdong-Hong Kong-Macao Greater Bay Area, Southeast Asia, and the Americas. It also expands into consumer healthcare sectors like health preservation and anti-aging treatments, creating a dual-driven innovation model of "medical + consumer" services. Shenzhen-Hong Kong Cell Valley has partnered with the Hong Kong Hospital Authority and medical institutions to establish a platform for cell product development and scientific research transformation. The initiative will gradually expand into the medical aesthetics and anti-aging sectors, developing precision health management services tailored for consumer markets. Leveraging Qianhai's cross-border service advantages, it aims to extend its reach to overseas markets by providing technological solutions and premium healthcare services.